Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 7, 2008
JNCI Journal of the National Cancer Institute 2008 100(20):1417; doi:10.1093/jnci/djn392
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/20/1417-b    most recent
djn392v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

MEMO TO THE MEDIA

Tamoxifen Chemoprevention Associated with Earlier Diagnosis of Estrogen Receptor-Negative Breast Cancer

The first 10% of the full text of this article appears below.

Women at elevated risk of breast cancer who had been randomly assigned to tamoxifen treatment and then developed estrogen receptor (ER)–negative breast cancer were diagnosed earlier than women who had been randomly assigned to take a placebo and then developed . . . [Full Text of this Article]

Contact:

Citation:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor–Negative Breast Cancer
Yu Shen, Joseph P. Costantino, and Jing Qin
J Natl Cancer Inst 2008 100: 1448-1453. [Abstract] [Full Text] [PDF]